Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
ConditionPlaque Psoriasis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-79
SponsorOruka Therapeutics, Inc.
About this trial
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
Eligibility criteria
Qualifiers
Participants ≥ 18 and < 80 years of age at the time of consent
Have a diagnosis of plaque psoriasis for > 6 months
BSA ≥ 10%, and
PASI ≥ 12, and
Disqualifiers
Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis)
Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
A known hypersensitivity to any components of the ORKA-002 drug product
Trial design
Treatments tested in this trial
- ORKA-002
- Placebo
Treatment groups
160 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov